ESC 2019: DAPA-HF: The Dapaglifozin and Prevention of Adverse Outcomes in Heart Failure Trial

Published: 03 Oct 2019

  • Views:

    Views Icon 21
  • Likes:

    Heart Icon 0


Prof Frank Ruschitzka (University Hospital Zurich, Zurich, CH) discussion DAPA-HF - The dapagliflozin and prevention of adverse outcomes in heart failure trial at ESC 2019.


This interview is a component of a wider Radcliffe Education programme entitled 'Current and emerging data on SGLT" inhibitors in heart failure'.

Certified accreditation of the full programme is pending following application to the European Board for Accreditation in Cardiology (EBAC)

This video is partially funded by an unrestricted education grant from AstraZeneca.